Nacimbio to Showcase Key Projects and New Development

Nacimbio to Showcase Key Projects and New Development


Nacimbio, the pharmaceutical holding company of Rostec State Corporation, participates in the “PharmMedProm-2017” exhibition held as part of the “Russian Week of Healthcare”. The company presents key projects, new promising development and products that the market already knows and that show high sales performance in the public sector and commercial market. 

“This year, the company’s exposition is an interactive platform where the holding and key production enterprises forming part of it may present their products and innovations”, – Director General of Nacimbio Andrey Zagorskiy commented on the participation in the exhibition 

The latest production site of Nacimbio – FORT LLC – presents Ultrix and Sovigripp flu vaccines in prefilled syringes supplied for the population vaccination as part of the National Immunization Schedule. 

Exhibition visitors also have a chance to see new development by Sintez JSC. Polymer blood containers unparalleled in this country were registered in October 2017 and will hit the market already next year. These disposable contains make donor blood collection safer and more convenient both to patients and health care providers. The new items are the first domestic containers to enable leukoreduced donor blood collection and reduce the risk of patient’s complications.

The largest home producer of immunobiological preparations Microgen RPA presents 14 mono- and polyphagous preparations for infectious disease control at the combined exposition. New holding development – Difag and Enterobacter – undergo clinical studies. Difag will be used to fight acinetobacteria and Ps. aeroginosa, while Enterobacter will, for the first time in the global practice, combine an entire complex of Enterobacter bacteriophages. This preparation is an effective treatment of acute intestinal diseases, biliary and urinary infections, purulent lesions of skin, brain tunics, sepsis, hospital infections. 

“With the growing antibiotic resistance, bacteriophage treatment is a promising method of bacterial infection control. This year, bacteriophages have been included in the strategy of prevention of antimicrobial resistance spread in the Russian Federation until 2030 initiated by WHO in all countries”, – said Kirill Gaidash, Director General of Microgen.

“PharmMedProm-2017” exhibition will last until 08 December 2017.